Detalhe da pesquisa
1.
Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019.
Int J Cancer
; 151(8): 1345-1354, 2022 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35603979
2.
Access to innovation through the national early access program and clinical trials for patients with malignant melanoma.
Cancer
; 127(13): 2262-2270, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33764524
3.
Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab.
Cancer Chemother Pharmacol
; 92(3): 223-228, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37439816
4.
[Administrative delays of temporary recommendation for use: Impact on access to innovation in melanoma]. / Délais administratifs des RTU, effet sur l'accès à l'innovation dans le mélanome.
Bull Cancer
; 109(1): 28-37, 2022 Jan.
Artigo
em Francês
| MEDLINE | ID: mdl-34972538
5.
[Early access to innovative drugs, ethical impacts]. / Accès précoce aux médicaments innovants, impacts éthiques.
Rev Prat
; 72(8): 841-845, 2022 Oct.
Artigo
em Francês
| MEDLINE | ID: mdl-36511980
6.
Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Eur J Cancer
; 149: 82-90, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33838392
7.
Response to the letter: Re: Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years.
Eur J Cancer
; 156: 222-224, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34419329
8.
The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.
Cancer Chemother Pharmacol
; 83(5): 1003-1005, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30830289